Lupin launches generic Ancobon

David Salazar

1/8/2018

Lupin has added to its generics lineup with its version of Valeant Pharmaceuticals’ Ancobon (flucytosine) capsules. The drug is indicated to treat serious infections caused by candida and/or Cryptococcus.

The product will be available from Lupin in 250- and 500-mg dosage strengths. These dosage strengths had U.S. sales of roughly $48 million for the 12 months ended October 2017, according to IQVIA data.

Sycamore Partners reportedly working on financing to acquire Walgreens

A potential buyout reportedly would include terms loans, a bridge loan and asset-based lending.

Walgreens buyout reportedly could result in three divisions

Walgreens’ three core segments—U.S. pharmacy retailer Walgreens, U.K.-based Boots and specialty unit Shields Health Solutions—could become three independent divisions, per a report.

Ulta Beauty sets date for experiential beauty event

Ulta Beauty World will take place on April 26 in San Antonio, Texas.

Walgreens reportedly close to roughly $10B deal to go private

The deal could be finalized by Thursday, per a WSJ report.

CVS Health to open smaller format stores

Each location will average less than 5,000 square feet and will feature a full-service pharmacy with limited over-the-counter products available for purchase.